Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Genes encoding apoptosis-inducing proteins are postulated to be candidate tumour suppressors. The identification of such proteins may benefit the early diagnosis and therapy of tumours. In the present study, we characterized the function of a novel human BMSC (bone marrow stromal cell)-derived protein {IPP5 [inhibitor-5 of PP1 (protein phosphatase 1)]} by large-scale random sequencing of a human BMSC cDNA library. hIPP5 (human
IPP5
) cDNA encodes a protein of 116 amino acid residues, which shares high homology with human PPI-1 (inhibitor-1 of PP1). The effect of
IPP5
on apoptosis and the underlying molecular mechanisms were investigated by overexpression of
IPP5
in HeLa cells, a human cervical carcinoma cell line. Our results showed that overexpression of active mutant
IPP5
inhibited anchorage-dependent growth and induced apoptosis in HeLa cells, which may be attributed to the up-regulation of p21(waf/cip1) (a 21 kDa cell-cycle regulatory protein), p53 and
Bcl-2
-antagonist/killer, and down-regulation of
Bcl-2
and Bcl-X(L). We also showed that the expression of active mutant
IPP5
in HeLa cells was further enhanced on TNF (tumour necrosis factor) treatment and overexpression of active mutant
IPP5
sensitized HeLa cells to TNF-induced JNK (c-Jun N-terminal kinase) and p38 activation as well as TNF-mediated apoptosis. Thus overexpression of active mutant
IPP5
may increase cell susceptibility to TNF-induced apoptosis by the activation of p38 and JNK pathways. In addition,
IPP5
active mutant could interact with PP1alpha as demonstrated by the co-precipitation assay.
...
PMID:Effect of IPP5, a novel inhibitor of PP1, on apoptosis and the underlying mechanisms involved. 1987 72